期刊
CANCER MANAGEMENT AND RESEARCH
卷 14, 期 -, 页码 1043-1061出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S267260
关键词
pancreatic cancer; immunotherapy; immune checkpoint inhibitors; cancer vaccines; adoptive cellular immunotherapy; microsatellite instability
类别
This article presents the latest advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using a combination of immunotherapy with other interventions such as chemotherapy and/or radiation. The role of the tumor microenvironment as a barrier to immunotherapy efficacy is outlined, and the use of immunotherapy biomarkers to detect response is examined.
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and fourth most common cause of death in developed countries. Despite improved survival rates after resection combined with adjuvant chemotherapy or neoadjuvant chemotherapy, recurrence still occurs in a high percentage of patients within the first 2 years after resection. Immunotherapy aims to improve antitumor immune responses and reduce toxicity providing a more specific, targeted therapy compared to chemotherapy and has been proved an efficient therapeutic tool for many solid tumors. In this work, we present the latest advances in PDAC treatment using a combination of immunotherapy with other interventions such as chemotherapy and/or radiation both at neoadjuvant and adjuvant setting. Moreover, we outline the role of the tumor microenvironment as a key barrier to immunotherapy efficacy and examine how immunotherapy biomarkers may be used to detect immunotherapy's response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据